Overall, although serum levels of both ALT and GGT are useful markers for the noninvasive surveillance of the hepatic histological response to treatment in patients with NAFLD, we first compared the clinical significance among different liver biochemistry markers, including serum ALT and GGT, in the management of metabolic abnormalities during NAFLD monitoring and demonstrated that their associations with metabolic parameters were different. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.